Data-Driven Insights
Posts for tag: patient journey
December 12, 2018 | Gary Palgon
In this post IntegriChain Senior Vice President of Sales, Gary Palgon, shares the trending topic's from the 2018 CBI Life Sciences Trade & Channel conference held in Philadelphia, Pa December 11-12.
December 10, 2018 | Brandon Underwood
An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty data contracting decisions enable diagnostic patient journey insights that help specialty brands save patient days of therapy.
August 3, 2018 | Sean McCarthy
There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals. Each key opportunity to improve patient initiation is related to a friction point in the patient journey. In this post, IntegriChain Patient Access Segment Leader Sean McCarthy provides an overview of these key opportunities and the potential of analytics to unlock efficiencies for specialty brands.
March 21, 2017 | Brandon Underwood
Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.